Search the Newsreel

Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?

What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera (ABCL) saw its stock price jump by 64% last week, becoming the top-performing mid-cap stock in the US market, following strong phase 2 clinical trial results for its drug candidate ABCL635 for hot flashes in menopausal women. The drug successfully reduced hot flash …

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

ETFs Investing in RTW Biotech Opportunities Ltd USD Stocks

RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker

RA Capital Management, L.P., along with associated entities and individuals, has reported a 9.99% beneficial ownership stake in Adicet Bio, Inc. (ACET) as of June 30, 2026. This ownership includes common stock and pre-funded warrants, which contain a "Beneficial Ownership Blocker" preventing exercises that …

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

Iovance Biotherapeutics, Inc. stock jumps 130% in 2026 but RSI screams overbought

Trading the Move, Not the Narrative: (INBX) Edition

This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.

Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands

Biohaven (BHVN) has expanded its oncology collaboration with Regeneron Pharmaceuticals, leading to recent stock momentum despite a longer history of weak returns and losses. Simply Wall St's Discounted Cash Flow (DCF) model estimates BHVN to be 73% undervalued with a fair value of $54.53 …

VRXA: Veraxa Biotech AG - Comparison to Industry

Zimmer Biomet - ZIM - Stock Price & News

This article provides a detailed financial overview of Zimmer Biomet (ZIM), a company specializing in orthopedic reconstructive products. It includes stock performance metrics, market capitalization, key financial ratios like revenue, net income, and EPS, along with annual and quarterly growth comparisons. The content also …

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2

Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) but has reduced the target price for the stock to $2. This adjustment reflects a revised outlook on the company's valuation while maintaining a positive long-term perspective.

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

KN Agri Resources and Ajooni Biotech Publish Unaudited Quarterly Results in Newspapers

Biote Corp. executive chairman Marc Beer buys over $202k in shares

Biote Corp.'s executive chairman, Marc Beer, recently purchased 131,950 shares of Class A Common Stock worth over $202,000. These transactions occurred on August 10 and 11, 2026, amidst a 44% year-to-date decline in the stock's value. Despite a recent revenue decline reported in Q2 …

Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Just Slashed This Year's Revenue Estimates By 22%

Vir Biotechnology (VIR) Q2 Profit Turn Raises The Question Of Whether Shares Are Still Cheap

Theravance Biopharma Deal Faces Investor Probe

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's …

How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results

Forte Biosciences reported increased net losses in Q2 and H1 2026 but saw a slight improvement in basic loss per share due to share count adjustments. The company's investment narrative is now heavily tied to its pending sale to argenx and the cash tender …

Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada

Royal Bank of Canada upgraded Krystal Biotech (NASDAQ:KRYS) to a "moderate buy" rating, aligning with a generally bullish analyst consensus. The company, which has a market capitalization of $9.83 billion, recently reported quarterly earnings that beat expectations but revenue that slightly missed. Insider selling …

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

Walleye Capital LLC has invested $3.45 million in Upstream Bio (NASDAQ:UPB), acquiring a 0.92% stake. This investment comes as Upstream Bio continues to be unprofitable, though it recently beat earnings and revenue estimates. Analyst sentiment is mixed, with a consensus "Hold" rating despite varying …

Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX

Walleye Capital LLC has invested $2.44 million in REGENXBIO Inc. by acquiring 203,726 shares during the second quarter, making them one of many institutional investors in the company. REGENXBIO exceeded analyst expectations with its recent earnings report, posting $0.43 EPS and $108.02 million in …

Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX

Walleye Capital LLC has made a new investment of $1.68 million in Biodesix, Inc. (NASDAQ:BDSX), acquiring 74,447 shares, which represents about 0.72% of the company. Other institutional investors and hedge funds have also adjusted their holdings in Biodesix, which collectively owns 20.96% of the …

Technical Reactions to AVBP Trends in Macro Strategies

This article provides a technical analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP) trends, highlighting neutral near and mid-term readings but a potentially strong long-term positive bias. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The …

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, …

Banka BioLoo Publishes Q1 FY27 Unaudited Results in Line With SEBI Norms

147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired 147,000 shares of ImmunityBio, Inc. (IBRX) during the second quarter, valued at approximately $1.29 million. Institutional investors now hold 8.58% of the company, while corporate insiders own 66.10%, despite recent insider selling totaling about $3.92 million. ImmunityBio reported a …

CSTL (CSTL) insider and family trusts detail planned and recent stock sales

A recent SEC Form 144 filing indicates a planned sale of 25,792 shares of CSTL common stock, valued at $763,959.04, by an insider and related family trusts, to be executed around August 14, 2026, through Goldman Sachs & Co. LLC. The filing also details …

354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC

Walleye Capital LLC recently acquired 354,395 shares of BioAge Labs, Inc. (NASDAQ:BIOA) for approximately $8.7 million, representing 0.8% of the company. Other institutional investors also increased their stakes in the clinical-stage biotech firm. Analysts have a "Moderate Buy" consensus rating with an average price …

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate …